How patients should monitor their health while taking fostatinib/fotantinib

During the treatment of chronic immune thrombocytopenia (ITP) with Fostamatinib, patients should undergo systematic health monitoring to ensure both efficacy and safety. Fostatinib works by regulating the activity of the immune system. Long-term use may affect blood pressure, liver function and blood indicators, so it is particularly critical to establish an individualized monitoring plan. Before starting treatment, doctors usually assess the patient's basic blood pressure, liver and kidney function, and blood routine indicators for subsequent comparison and evaluation of the effects of the drug.

During the first 8 weeks of medication, it is recommended to monitor blood pressure every 2 to 4 weeks. If there is a mild increase, it can be improved through diet control, limiting salt intake, or using antihypertensive drugs. For patients with a history of hypertension, more frequent testing is needed to avoid potential cardiovascular risks. In terms of liver function, it is recommended to detect ALT, AST and bilirubin levels before and once a month after medication. Once there is a significant increase, dose adjustment or treatment suspension should be considered. Some patients may experience mild fatigue or loss of appetite. If it lasts for too long, blood tests should be further evaluated to rule out anemia or inflammatory reactions.

In addition, the dynamic changes in platelet number are an important indicator for evaluating the efficacy of fostatinib. Generally, within 2 to 4 weeks after taking the medication, the doctor will decide whether to continue the current dose or make fine adjustments based on platelet recovery. Patients should not increase or decrease the dose or discontinue medication on their own, otherwise the disease may recur or the efficacy may decrease. In addition to laboratory tests, patients should also pay attention to physical signals on a daily basis, such as dizziness, stomach discomfort, rash or unusual fatigue, and communicate with their doctor in a timely manner. For long-term treatment users, it is recommended to conduct a comprehensive physical examination every three months to ensure that cardiovascular, liver and kidney functions are maintained within a safe range.

Taken together, scientific monitoring and regular follow-up are key to ensuring the safe and effective use of fostatinib, which can also help doctors optimize treatment plans and improve patients' quality of life.

Reference materials:https://go.drugbank.com/drugs/DB12010